SCHEMBL6499366

SCHEMBL6499366

CC(C)(C)OC(=O)Nc1cccc(CCN(C(=O)OC(C)(C)C)c2ccc(N)cn2)n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.37
MAPKAPK2 P49137 8/20 0.36
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
CCR2 P41597 1/20 0.34
HDAC1 Q13547 2/20 0.33
GLS O94925 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
SYK P43405 1/20 0.33
GSK3B P49841 1/20 0.32
DYRK1A Q13627 1/20 0.32
MAPK8 P45983 1/20 0.32
CHRNB2 P17787 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
SCN9A Q15858 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489886 0.87 NR3C2 (0.39) NR3C2MAPKAPK2CCR2HDAC1GLS
SCHEMBL6499711 0.82 SIRT1 (0.42) MAPKAPK2CCR2HDAC1HDAC6
SCHEMBL6500770 0.80 ITGB3 (0.41) NR3C2MAPKAPK2CCR2HDAC1MAPK8
SCHEMBL29392374 0.80 SSTR4 (0.34) CKS1BSKP1SKP2HDAC1HDAC8
SCHEMBL23620907 0.80 SSTR4 (0.34) CKS1BSKP1SKP2HDAC1HDAC8
SCHEMBL6677518 0.79 NR3C2 (0.39) NR3C2HDAC1GLSHDAC8HDAC6
SCHEMBL6680383 0.79 MAPKAPK2 (0.41) NR3C2MAPKAPK2CCR2HDAC1GLS
SCHEMBL6492788 0.78 NR3C2 (0.45) NR3C2MAPKAPK2CCR2HDAC1GLS
SCHEMBL6680385 0.77 MAPKAPK2 (0.38) NR3C2MAPKAPK2CKS1BSKP1SKP2
SCHEMBL6501309 0.77 TP53 (0.34) HDAC1HDAC8HDAC6GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 NR3C2 725/4885MAPKAPK2 3154/4885CKS1B 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.